Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort.

"Disclosure statement : The authors have declared no conflicts of interest."

"Funding This work was made possible by the support of the Sophia Children’s Hospital Fund [B18-04], NVLE (Dutch patient organization for Lupus, APS, Scleroderma and MCTD) [BP12-1-261] and Dutch Arthritis Society [CO-19-001]. The research was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. N.M.I. received financial support from the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Tourism. Disclosure statement: The authors have declared no conflicts of interest. Study approval: Written informed consent was obtained from all participants in compliance with the Declaration of Helsinki. The study was approved by the medical ethics review committee of the Erasmus University Medical Center, Rotterdam, the Netherlands (MEC-2019-0412)."